文献速递神经肿瘤

近距离放疗辅助治疗复发非典型和恶性脑膜瘤

Brachytherapy as an Adjuvant for Recurrent Atypical and Malignant Meningiomas.
PubMed 文献 · Neurosurgery · 2019-01-01

这项回顾性研究分析了2002至2014年间15例复发高级别脑膜瘤患者,在切除术后术中放置I-125或Cs-131近距离放疗粒子。中位年龄68.8岁,既往中位开放手术2次、放疗中位剂量55 Gy;

要点

  • 复发高级别脑膜瘤切除后术中放置永久粒子近距离放疗可作为辅助治疗选择
  • 2.5年生存率II级56%、III级17%,生存与年龄相关而非病理级别

核心结论

  • 永久性放疗粒子植入近距离放疗为复发脑膜瘤提供可行替代治疗,但伴显著伤口感染和再手术临床风险。

研究设计与样本

  • 回顾性病历回顾研究,纳入2002至2014年在本机构接受切除并术中放置近距离放疗粒子的复发高级别脑膜瘤患者15例。
  • 患者中位年龄68.8岁,接受I-125(n=13)或Cs-131(n=2)粒子治疗。
  • 肿瘤为复发II级(n=8)或III级(n=7)脑膜瘤,起源部位包括凸面(3)、大脑镰(3)、额叶(2)、枕叶(1)、顶叶(2)、蝶骨翼(2)和颞叶(2)。
  • 患者既往中位开放手术2次,近距离放疗前接受局部放疗中位剂量55 Gy。

主要发现

  • 2.5年生存率II级病变为56%,III级病变为17%。
  • 生存与患者年龄显著相关,但与肿瘤病理无关。

临床怎么用

  • 对于复发高级别脑膜瘤,尤其多次手术和放疗后,可考虑切除联合术中永久粒子近距离放疗作为辅助治疗。
  • 患者年龄可能影响生存获益,选择病例时应综合评估。

局限性

  • 回顾性 chart review,样本量小(15例),证据级别有限。
  • 单中心经验,2002至2014年数据,外推性需谨慎。
  • 未设对照组,无法直接比较近距离放疗与其他辅助治疗的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrent atypical and malignant meningiomas have poor outcomes with surgical therapy alone. Neither adjuvant chemotherapy nor postoperative radiation therapy remedies this problem. OBJECTIVE: To evaluate our experience with the treatment of 15 patients treated with I-125 or Cs-131 brachytherapy radiation seeds as an adjuvant in these difficult cases. METHODS: Patients with high-grade recurrent meningioma who underwent resection and intraoperative placement of brachytherapy seeds at our institution from 2002 to 2014 were identified and studied by retrospective chart review. RESULTS: Fifteen patients with median age of 68.8 yr were treated with I-125 (n = 13) or Cs-131 (n = 2) brachytherapy seeds for cases of recurrent, grade II (n = 8), or grade III (n = 7) meningioma at our institution from 2002 to 2014. These lesions originated from a variety of locations including, convexity (3), falcine (3), frontal (2), occipital (1), parietal (2), 2 sphenoid wing (2), and temporal (2), based recurrent meningiomas. Patients had a median of 2 prior open surgical interventions and received local radiation therapy with a median dose of 55 Gy prior to brachytherapy. Survival at 2.5 yr was 56% for grade II and 17% for grade III lesions. Survival was significantly associated with patient age but not tumoral pathology. Forty percent of patients required reoperations for wound complications following brachytherapy. CONCLUSION: Brachytherapy with implantation of permanent radiation seeds provides a viable alternative treatment for recurrent meningioma while carrying a significant clinical risk of wound infection and need for reoperation.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Koch MJ, Agarwalla PK, Royce TJ, et al. Brachytherapy as an Adjuvant for Recurrent Atypical and Malignant Meningiomas. Neurosurgery. 2019. PMID: 31329941. doi:10.1093/neuros/nyz115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。